Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 15/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 13/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 13/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | ASPH | Q12797 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8242414 | 0.88 | HDAC1 (0.78) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1402953 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1402955 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL5020683 | 0.87 | HDAC1 (1.00) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1403166 | 0.85 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1403168 | 0.85 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1403297 | 0.85 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1402924 | 0.85 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1402923 | 0.85 | HDAC1 (0.74) | HDAC1HDAC6HDAC8HDAC2HDAC3 | |
| SCHEMBL1403271 | 0.85 | HDAC1 (0.73) | HDAC1HDAC6HDAC8HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-10799469-B2 | Combination therapies using HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20190216755-A1 | Combination Therapies Using HDAC Inhibitors | TOPOTARGET UK LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-10285959-B2 | Combination therapies using HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2019-05-14 | — | — | US | disclosed |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-9980957-B2 | Histone deacetylase (HDAC) inhibitors for the treatment of cancer | TOPOTARGET UK LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20170172997-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | TOPOTARGET UK LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| US-9603926-B2 | Histone deacetylase (HDAC) inhibitors for the treatment of cancer | TOPOTARGET UK LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20080213399-A1 | Histone deacetylase inhibitor, and epidermal growth factor receptor inhibitor; Cisplatin, 5-Fluorouracil, Oxaliplatin, Topotecan, Gemcitabine, Docetaxel, Doxorubicin, Tamoxifen, Dexamethasone, 5-Azacytidine, Chlorambucil, Fludarabine, Tarceva (reg) , Alimta (reg) , Melphalan | TOPOTARGET UK LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
| US-7407988-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407988-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| US-7183298-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-7183298-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| WO-2005105066-A2 | HISTONE DEACETYLASES INHIBITORS AGAINST HYPERLIPIDAEMIAS, ATHEROSCLEROSIS, CARDIOVASCULAR DISEASES | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC8 7/4885 |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC8 7/4885 |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 10/4885HDAC8 4/4885 |
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC8 7/4885 |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 10/4885HDAC8 4/4885 |
| US-10285959-B2 | Combination therapies using HDAC inhibitors | HDAC4, HDAC6, HDAC9 | HDAC1 4/4885HDAC6 2/4885HDAC8 7/4885 |
| US-20190216755-A1 | Combination Therapies Using HDAC Inhibitors | HDAC4, HDAC6, HDAC9 | HDAC1 4/4885HDAC6 2/4885HDAC8 7/4885 |
| US-20080213399-A1 | Histone deacetylase inhibitor, and epidermal growth factor receptor inhibitor; Cisplatin, 5-Fluorouracil, Oxaliplatin, Topotecan, Gemcitabine, Docetaxel, Doxorubicin, Tamoxifen, Dexamethasone, 5-Azacytidine, Chlorambucil, Fludarabine, Tarceva (reg) , Alimta (reg) , Melphalan | BRDT, HDAC4, HDAC1 | HDAC1 3/4885HDAC6 9/4885HDAC8 4/4885 |
| US-20170172997-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | HDAC1, HDAC4, BRDT | HDAC1 1/4885HDAC6 5/4885HDAC8 13/4885 |
| US-10799469-B2 | Combination therapies using HDAC inhibitors | HDAC4, HDAC6, HDAC9 | HDAC1 4/4885HDAC6 2/4885HDAC8 7/4885 |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.